AMC Capital IV SCSp, advised by Mezzanine Management, has committed EUR 10.0 million of growth capital and minority equity to Optimapharm d.d. the leading Clinical Research Organisation (“CRO”) in the Adriatic region, with an expanding footprint over Central and Eastern Europe. It is Mezzanine Management’s first deal in Croatia.
Established in 2006 by Gordana Gregurić Čičak and Igor Čičak, Optimapharm is a full-service CRO headquartered in Zagreb, Croatia.
It provides tailored solutions for its clients and has a high-level of expertise in managing trials across Europe. It has unrivalled access to patients in the emerging markets of Central, Eastern and South Eastern Europe.